12 April 2024 in Advances in Biochemistry
Albuminuria is the gold standard for the screening of microalbuminuria, a biomarker of early onset of nephropathy during sickle cell anemia (SCA). Nephropathy increase morbidity and mortality of SCA in the absence of appropriate treatment. However, albuminuria is not readily available or affordable in resource-limited countries, so in 2012 Kidney Diseases Improving Global Outcomes (KDIGO) proposed using proteinuria at a threshold of 150 mg/g urine creatinine to screen for microalbuminuria in these settings. The aim of this study was therefore to assess the performance of proteinuria in screening microalbuminuria in sub-Saharan Senegalese sickle cell patients. Albuminuria in recruited SS sickle cell patients was expressed as a urine albumin-to-creatinine ratio (UACR) and proteinuria as a urine proteins-to-creatinine ratio (UPCR). The prevalence of microalbuminuria, Cohen's kappa coefficient and areas under the curve (AUC) were then determined to assess the performance of proteinuria in detecting microalbuminuria. A total of 150 patients with a median age of 20 years [minimum-maximum: 4-57] and a female proportion of 51.33% were included in the study. Microalbuminuria was present in 42.38% (n=64) of subjects according to the UPCR. The Cohen's kappa coefficient was 0.41 [IC95%: 0.27-0.56] and the AUC 0.71 [IC95%: 0.64 - 0.81] with UPCR 150mg/g. The best Cohen's kappa coefficient and AUC were observed with an UPCR threshold of 135 mg/g. Our results confirm that proteinuria is useful in screening for microalbuminuria and show that RPCU 135 mg/g would be the optimal cut-off for detecting microalbuminuria in Senegalese sickle cell anemia patients.
13 September 2026 in Scientific Reports
ASAndrea Regina Gnilane Sene
Andrea Regina Gnilane Sene
CLCheikh Ahmed Tidiane Ly
+11
Non-fasting lipid profiling is now widely recommended; however, reference intervals (RIs) are notably lacking in sub-Saharan Africa, particularly for emerging lipid biomarkers (non-HDL-C, sdLDL-C, TRL-C). This study aimed to establish these values in Senegal and propose pragmatic clinical decision thresholds. As part of the SEN-GENOME project, we conducted a study involving 746 adults, including a reference subgroup of 241 strictly healthy individuals. Non-fasting specimens were collected to analyse conventional and emerging lipid parameters using the Sampson-NIH equation. RIs were calculated in accordance with the CLSI EP28-A3c protocol. The upper reference limit for triglycerides 2.73 mmol/L confirms the clinical tolerance of the non-fasting state. However, the statistical RIs (2.5–97.5th percentiles) for total cholesterol and LDL-C significantly exceeded the NCEP ATP III risk thresholds. Furthermore, the general population’s values exhibited a marked metabolic drift compared to the healthy reference group. Strict reliance on statistical RIs risks normalising atherogenic profiles. We advocate for the adoption of clinical decision thresholds based on the median (optimal threshold) and the 75th percentile (alert threshold) for extended lipid profiling. This approach, including emerging lipid parameters, is essential for improving early cardiovascular risk detection.